Millendo Therapeutics initiates pivotal phase 2b/3 clinical study of livoletide
Millendo Therapeutics announced it has initiated its pivotal Phase 2b/3 clinical study investigating livoletide (AZP-531) in patients with Prader-Willi syndrome. The study will evaluate the safety and efficacy of livoletide on food-related behaviors in PWS patients. March 19, 2019